High dose antithrombin III inhibits HMGB1 and improves endotoxin-induced acute lung injury in rats

Intensive Care Medicine

Volumn 34, Issue 2, 2008, Pages 361-367

  Hagiwara, Satoshi ^a   Iwasaka, Hideo ^a   Matsumoto, Shigekiyo ^a   Noguchi, Takayuki ^a  

^a OITA UNIVERSITY   (Japan)

Author keywords

Antithrombin III; Cell signal; High mobility group box 1; Inflammation; Lipopolysaccharide

Indexed keywords

ANTITHROMBIN III; CYTOKINE; ENDOTOXIN; HIGH MOBILITY GROUP B1 PROTEIN; I KAPPA B; LIPOPOLYSACCHARIDE; PROTEIN P42;

ACUTE LUNG INJURY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL LYSATE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MACROPHAGE; MALE; NONHUMAN; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; RAT; SEPSIS; STATISTICAL SIGNIFICANCE; WESTERN BLOTTING;

ANALYSIS OF VARIANCE; ANIMALS; ANTITHROMBIN III; BLOTTING, WESTERN; ENZYME-LINKED IMMUNOSORBENT ASSAY; HMGB1 PROTEIN; IMMUNOENZYME TECHNIQUES; LIPOPOLYSACCHARIDES; MALE; PROSPECTIVE STUDIES; RANDOM ALLOCATION; RATS; RATS, WISTAR; RESPIRATORY DISTRESS SYNDROME, ADULT;

EID: 38849155079     PISSN: 03424642     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00134-007-0887-5     Document Type: Article

References (31)

1. Andrews P, Azoulay E, Antonelli M, Brochard L, Brun-Buisson C, Dobb G, Fagon JY, Gerlach H, Groeneveld J, Mancebo J, Metnitz P, Nava S, Pugin J, Pinsky M, Radermacher P, Richard C, Tasker R (2006) Year in review in intensive care medicine, 2005. II. Infection and sepsis, ventilator-associated pneumonia, ethics, haematology and haemostasis, ICU organisation and scoring, brain injury. Intensive Care Med 32:380-390
2. Andrews P, Azoulay E, Antonelli M, Brochard L, Brun-Buisson C, Dobb G, Fagon JY, Gerlach H, Groeneveld J, Mancebo J, Metnitz P, Nava S, Pugin J, Pinsky M, Radermacher P, Richard C, Tasker R, Vallet B (2005) Year in review in intensive care medicine, 2004. I. Respiratory failure, infection, and sepsis. Intensive Care Med 31:28-40
3. Iba T, Kidokoro A, Yagi Y (1998) The role of the endothelium in changes in procoagulant activity. J Am Coll Surg 87:321-329
4. Freeman BD, Zehnbauer BA, Buchman TG (2003) A meta-analysis of controlled trials of anticoagulant therapies in patients with sepsis. Shock 20:5-9
5. Matthay MA (2001) Severe sepsis: a new treatment with both anticoagulant and anti-inflammatory properties. N Engl J Med 344:759-762
6. Uchiba M, Okajima K (1997) Antithrombin III (AT III) prevents LPS-induced pulmonary vascular injury: novel biological activity of AT III. Semin Thromb Hemost 23:583-590
7. Totzke G, Schobersberger W, Schloesser M, Czechowski M, Hoffmann G (2001) Effects of antithrombin III on tumor necrosis factor-alpha and interleukin-1beta synthesis in vascular smooth muscle cells. J Interferon Cytokine Res 21:1063-1069
8. Inthorn D, Hoffmann JN, Hartl WH, Muhlbayer D, Jochum M (1998) Effect of antithrombin III supplementation on inflammatory response in patients with severe sepsis. Shock 10:90-96
9. Yang S, Hauptman JG (1994) The efficacy of heparin and antithrombin III in fluid-resuscitated cecal ligation and puncture. Shock 2:433-437
10. Iba T, Kidokoro A, Fukunaga M, Nagakari K, Suda M, Yoshikawa S, Ida Y (2005) Antithrombin ameliorates endotoxin-induced organ dysfunction more efficiently when combined with danaparoid sodium than with unfractionated heparin. Intensive Care Med 8:1101-1108
11. Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, Chalupa P, Atherstone A, Penzes I, Kubler A, Knaub S, Keinecke HO, Heinrichs H, Schindel F, Juers M, Bone RC, Opal SM, KyberSept Trial Study Group (2001) High-dose antithrombin III in severe sepsis. A randomized controlled trial. J Am Med Assoc 286:1869-1878
12. Iba T, Kidokoro A (2004) What can we learn from the three mega-trials using anticoagulants in severe sepsis? Shock 22:508-512
13. Wiedermann CJ, Hoffmann JN, Juers M, Ostermann H, Kienast J, Briegel J, Strauss R, Keinecke HO, Warren BL, Opal SM, KyberSept Investigators (2006) High-dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. Crit Care Med. 34:285-292
14. Mammen EF (1998) Antithrombin III and sepsis. Intensive Care Med 7:649-650
15. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, Frazier A, Yang H, Ivanova S, Borovikova L, Manogue KR, Faist E, Abraham E, Andersson J, Andersson U, Molina PE, Abumrad NN, Sama A, Tracey KJ (1999) HMG-1 as a late mediator of endotoxin lethality in mice. Science 285:248-251
16. Bustin M (1999) Regulation of DNA-dependent activities by the functional motifs of the high-mobility-group chromosomal proteins. Mol Cell Biol 19:5237-5246
17. Fiuza C, Bustin M, Talwar S, Tropea M, Gerstenberger E, Shelhamer JH, Suffredini AF (2003) Inflammation-promoting activity of HMGB1 on human micro vascular endothelial cells. Blood 101:2652-2660
18. Yu M, Wang H, Ding A, Golenbock DT, Latz E, Czura CJ, Fenton MJ, Tracey KJ, Yang H (2006) HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. Shock 26:174-179
19. Park JS, Gamboni-Robertson F, He Q, Svetkauskaite D, Kim JY, Strassheim D, Sohn JW, Yamada S, Maruyama I, Banerjee A, Ishizaka A, Abraham E (2006) High Mobility Group Box 1 protein (HMGB1) interacts with multiple Toll like receptors. Am J Physiol Cell Physiol 290:917-924
20. Sunden-Cullberg J, Norrby-Teglund A, Treutiger CJ (2006) The role of high mobility group box-1 protein in severe sepsis. Curr Opin Infect Dis 19:231-236
21. Ueno H, Matsuda T, Hashimoto S, Amaya F, Kitamura Y, Tanaka M, Kobayashi A, Maruyama I, Yamada S, Hasegawa N, Soejima J, Koh H, Ishizaka A (2004) Contributions of high mobility group box protein in experimental and clinical acute lung injury. Am J Respir Crit Care Med 170:1310-1316
22. Hatada T, Wada H, Nobori T, Okabayashi K, Maruyama K, Abe Y, Uemoto S, Yamada S, Maruyama I (2005) Plasma concentrations and importance of High Mobility Group Box protein in the prognosis of organ failure in patients with disseminated intravascular coagulation. Thromb Haemost 94:975-979
23. Sunden-Cullberg J, Norrby-Teglund A, Rouhiainen A, Rauvala H, Herman G, Tracey KJ, Lee ML, Andersson J, Tokics L, Treutiger CJ (2005) Persistent elevation of high mobility group box-1 protein (HMGB1) in patients with severe sepsis and septic shock. Crit Care Med 33:564-573
24. Yang H, Ochani M, Li J, Qiang X, Tanovic M, Harris HE, Susarla SM, Ulloa L, Wang H, DiRaimo R, Czura CJ, Wang H, Roth J, Warren HS, Fink MP, Fenton MJ, Andersson U, Tracey KJ (2004) Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci USA 101:296-301
25. Murakami K, McGuire R, Cox RA, Jodoin JM, Bjertnaes LJ, Katahira J, Traber LD, Schmalstieg FC, Hawkins HK, Herndon DN, Traber DL (2002) Heparin nebulization attenuates acute lung injury in sepsis following smoke inhalation in sheep. Shock 18:236-241
26. Yang H, Wang H, Tracey KJ (2001) HMG-1 rediscovered as a cytokine. Shock 15:247-253
27. Wang H, Vishnubhakat JM, Bloom O, Zhang M, Ombrellino M, Sama A, Tracey KJ (1999) Proinflammatory cytokines (tumor necrosis factor and interleukin 1) stimulate release of high mobility group protein-1 by pituicytes. Surgery 126:389-392
28. Kwak HJ, Song JS, Heo JY, Yang SD, Nam JY, Cheon HG (2005) Roflumilast inhibits lipopolysaccharide-induced inflammatory mediators via suppression of nuclear factor-kappaB, p38 mitogen-activated protein kinase, and c-Jun NH2-terminal kinase activation. J Pharmacol Exp Ther 315:1188-1195
29. Schottelius AJ, Mayo MW, Sartor RB, Baldwin AS (1999) Interleukin-10 signaling blocks inhibitor of kappaB kinase activity and nuclear factor kappaB DNA binding. J Biol Chem 274:1868-1874
30. Adcock IM (1997) Transcription factors as activators of gene transcription: AP-1 and NF-kappa B. Monaldi Arch Chest Dis 52:178-186
31. Dumitriu IE, Baruah P, Valentinis B, Voll RE, Herrmann M, Nawroth PP, Arnold B, Bianchi ME, Manfredi AA, Rovere-Querini P (2005) Release of high mobility group box 1 by dendritic cells controls T cell activation via the receptor for advanced glycation end products. J Immunol 174:7506-7515